Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06080035 · ClinicalTrials.gov registry record · NA
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
A NA study of Acne and Hyperpigmentation, sponsored by Integrative Skin Science and Research.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06080035: Completed NA study of Acne and Hyperpigmentation, sponsored by Integrative Skin Science and Research.
NCT06080035 is a NA study of Acne and Hyperpigmentation that has completed, run by Integrative Skin Science and Research. The registered enrollment target is 22 participants, below the 142-participant average among 26 other Acne trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06080035, a NA study of Acne and Hyperpigmentation, has completed, sponsored by Integrative Skin Science and Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.
Primary Outcome
Change in the appearance of pigment intensity (melanin measurement) of 3 pre-identified hyperpigmented lesions
Conditions Studied
Interventions
- OTHER Topical Cetyl Tranexamate Mesylate
Study Locations (1)
California
- Integrative Skin and Research - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2024-01-11 |
| Phase | NA |
What the finished NCT06080035 record still lists
NCT06080035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 142-participant average among 26 other Acne trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Acne appearing as the primary indexed condition, and to 1 intervention - of which Topical Cetyl Tranexamate Mesylate is the first listed.
NCT06080035 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06080035 about?
NCT06080035 is a clinical study titled "The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation". The purpose of this study is to assess the effects of Cetyl Tranexamate Mesylate on acne-related hyperpigmentation through a specific delivery form known as TeraCeutic TXVector.
What is the current status of trial NCT06080035?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2023-11-06. Estimated completion is 2024-01-11.
What conditions does trial NCT06080035 study?
This clinical trial studies the following conditions: Acne, Hyperpigmentation, Post-inflammatory Hyperpigmentation.
What interventions are being tested in trial NCT06080035?
The interventions under investigation include: Topical Cetyl Tranexamate Mesylate (OTHER).
Who is sponsoring clinical trial NCT06080035?
This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06080035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06080035's enrollment target sits among peer trials
22 22nd of 26 higher than 5 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
ACTIVE NOT RECRUITING · NA
-
An Exploratory Investigation of a Male Focused Skincare Supplement
COMPLETED · NA
-
An Exploratory Investigation of a Novel Skincare Regimen
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI